changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 05 February 2015
BTG plc (LSE: BTG), the specialist healthcare company, announces updated revenue guidance for the year ending 31 March 2015.
BTG's overall performance during the year to date has been in line with the Board's expectations. Full year revenue is now expected to be in the range £345m-£360m; previous guidance was £330m to £345m. The new guidance reflects the acquisition of PneumRx Inc, which completed on 7 January 2015, and a reversal of the adverse foreign exchange impact reported for the six months to 30 September 2014.
At its scheduled meeting today, the Board of BTG decided that in future BTG will not publish Interim Management Statements (IMSs). This follows the removal of the requirement for companies to publish IMSs, announced by the Financial Conduct Authority in November 2014. Scheduled communications will in future comprise: close period updates relating to the first six months and full year in early October and early April respectively; Interim and Final Results in November and May respectively; and an Annual General Meeting statement in July.
For further information please contact:
Andy Burrows, VP Corporate and Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7805 354134
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians. For further information about BTG please visit our website at www.btgplc.com.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com